阿立哌唑与齐拉西酮治疗首发精神分裂症对照研究

目的 比较阿立哌唑与齐拉西酮治疗首发精神分裂症的临床疗效及安全性.方法将60例精神分裂症患者随机分为两组,每组30例.研究组口服阿芷哌唑治疗,对照组口服齐拉西酮治疗,观察8周.于治疗前及治疗后第1周、2周、4周、8周末采用阳性与阴性症状量表评定临床疗效,副反应量表评定不良反应.结果 治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降(P<0.05或0.01),同期两组间比较差异均无显著性(P>0.05);治疗8周末.研究组显效率80.0%,对照组为76.7%,两组差异无显著性(X2=0.098,P>0.05).两组均存在轻度的抗胆碱能不良反应,研究组未出现锥体外系反应、肌强直、月经改变和泌乳、性欲改变、内分泌改变,体重增加发生率显著低于对照组(P<0.05),其他不良反应发生率两组差异无显著差异性(P>0.05).结论 阿立哌唑能有效改善首发精神分裂症的各种症状,疗效与齐拉西酮相当,是一种安全有效的新型抗精神病药物.

A controlled study of aripiprazole vs.ziprasidone in first-episode schizophrenia

Objective To compare the clinical efficacy and safety of aripiprazole vs. ziprasidone in the treatment of first-episode schizophrenia. Methods Sixty schizophrenia patients were randomly divided into two groups, research group （n：30） took orally aripiprazole and control group （n：30） did ziprasidone for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and ad- verse reactions with the Treatment Emergent Symptom Scale （TESS） before and at the end of the 1St, 2nd , 4th and 8th week treatment. Results After treatment the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment （P〈0.05 or 0.01）, contemporary group comparisons showed no significant differences （P〉0.05） ; the obvious effective rates were respectively 80. 0% in the research and 76.7% in the control group at the end of the 8th week,which showed no significant difference （x^2=0. 098, P〉0.05）. Both groups had mild antieholinergic adverse reactions, research group had no adverse reactions of extrapyramidal system, myotonia, menstrual changes and lactation, sexuality changes and endocrine alteration, and the incidence of weight gain was significantly lower in the research than in the control group （P〈0.05） and there were no significant differences in those of other adverse reactions （P〉0.05）. Conclusion Aripiprazole is effective on all symptoms of first-episode schizophrenia, its efficacy equivalent to ziprasidone and it is a safe and effective novel antipsyhotic.